Literature DB >> 1851504

Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients.

M Maes1, E Bosmans, E Suy, C Vandervorst, C Dejonckheere, J Raus.   

Abstract

To determine whether depression might be associated with serologic indices of autoimmune processes or active virus infections, we measured the following parameters in healthy controls, minor, simple major and melancholic patients: antiphospholipid (anticardiolipin, antiphosphatidylserine), antinuclear, and Epstein-Barr (EBV) and cytomegalovirus (CMV) antibodies. In addition, the soluble interleukin-2 receptor (sIL-2R) circulating levels in serum were measured and used as a marker of T cell activation. The anticardiolipin antibody titers were higher in melancholics than in healthy controls and minor depressives. Antinuclear antibodies were present significantly more frequently in depressed patients than in normal volunteers. The anticardiolipin and antinuclear antibody titers were significantly and positively intercorrelated. Depression is characterized by increased serum circulating levels of sIL-2Rs compared to the healthy state. Antinuclear-positive subjects exhibited significantly higher sIL-2Rs than those without detectable antinuclear titers. There was a positive correlation between anticardiolipin activity and sIL-2Rs. We found no evidence that depression is linked to EBV or CMV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851504     DOI: 10.1016/0165-0327(91)90060-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

Review 1.  The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.

Authors:  Gerwyn Morris; Ken Walder; Basant K Puri; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

2.  Atypical immune response to Epstein-Barr virus in major depressive disorder.

Authors:  Lorraine Jones-Brando; Faith Dickerson; Glen Ford; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Kevin Sweeney; Amalia Squire; Sunil Khushalani; Robert Yolken
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

3.  Lymphocyte subsets and interleukin-2 receptors in autistic children.

Authors:  D R Denney; B W Frei; G R Gaffney
Journal:  J Autism Dev Disord       Date:  1996-02

4.  Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol.

Authors:  M Maes; E Bosmans; H Y Meltzer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

5.  Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

Authors:  M Maes; H Y Meltzer; P Buckley; E Bosmans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  Anti-purkinje cell and natural autoantibodies in a group of psychiatric patients. Evidences for a correlation with the psychopathological status.

Authors:  Roberto Delle Chiaie; Brunella Caronti; Francesco Macrì; Sandra Campi; Marzia Marino; Alessandra Corrado; Maria Caredda; Massimo Biondi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-08-23

7.  Antinuclear antibodies in primary osteoarthritis of the knee: a case-control study.

Authors:  Rajalingham Sakthiswary; Shamala Rajalingam; Mohd Rosli Norazman; Heselynn Hussein
Journal:  EXCLI J       Date:  2012-09-07       Impact factor: 4.068

Review 8.  Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder.

Authors:  Eduardo Duarte-Silva; Michael Maes; Danielle Macedo; Wilson Savino; Christina Alves Peixoto
Journal:  Transl Psychiatry       Date:  2020-12-02       Impact factor: 6.222

Review 9.  Systems Genomics Support for Immune and Inflammation Hypothesis of Depression.

Authors:  Abhay Sharma
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.